https://www.cochrane.org/fr/CD013614/CENTRALED_quels-sont-les-benefices-et-risques-des-inhibiteurs-du-tnf-chez-les-personnes-atteintes-de 2025 United Kingdom review of literature french abstract psoriasis, nos arthritis disease risk assessment polyarthritis Polyarthritis psoriasis risks and benefits tumor necrosis factor persons Tumor Necrosis Factor Inhibitors anti-TNF
--- https://www.cochrane.org/fr/CD013715/CENTRALED_quels-sont-les-benefices-et-les-risques-des-inhibiteurs-du-facteur-de-necrose-tumorale-pour 2025 United Kingdom review of literature french abstract rheumatoid arthritis, systemic juvenile risk factors arthritis, nos unknown (origin) risk factor arthritis, juvenile Tumor Necrosis Factor Inhibitors risk assessment risks and benefits tumor necrosis factor
--- https://www.chu-lyon.fr/trouble-neurologique-fonctionnel-tnf 2024 France popular works nervous system diseases tumor necrosis factor neurology tumor necrosis factors functional disorder, nos
--- https://assurance-maladie.ameli.fr/etudes-et-donnees/2024-vedolizumab-ustekinumab-anti-tnf-grossesse-mici 2024 France scientific and technical information safety TNF Gene Ustekinumab inflammatory bowel disease, nos tumor necrosis factor Institutional Review Board Independent Ethics Committee Notification of Safety Information
Documentation Physically Feel in Bad Condition tumor necrosis factors Safety Report Clinical Trial Notification of Safety or Other Trial Information Documentation chronic disease, nos Vedolizumab research report vedolizumab disease Tumor Necrosis Factor anti-TNF Ustekinumab Chronic Disease Pregnant People inflammatory bowel diseases vedolizumab pregnancy, nos albumin/globulin ratio chronic disease Gravida